Quotes 5-day view Delayed Nasdaq
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
65.71(c)
66.9(c)
67.18(c)
74.64(c)
79.8(c)
Last
318 840
545 775
397 539
617 691
539 540
Volume
-1.17% +1.81% +0.42% +11.10% +6.91% Change
Sales 2020
21,0 M - 15,5 M
Net income 2020
-44,9 M - -33,0 M
Net cash position 2020
362 M - 267 M
P/E ratio 2020
-75,5x
Yield 2020
-
Sales 2021
-
-
-
Net income 2021
-104 M - -76,9 M
Net cash position 2021
261 M - 192 M
P/E ratio 2021
-37,5x
Yield 2021
-
Capitalization
3 825 M 3 825 M 2 815 M
EV / Sales 2020
165x
EV / Sales 2021
-
Nbr of Employees
71
Free-Float
78,4%
SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing medicines for patient suffering from rare diseases and cancer. The Company has a portfolio of small molecule targeted oncology product candidates and other programs addressing genetically defined cancers. Its provides Nirogacestat, which is an oral, small molecule gamma...
Notations Surperformance© of SpringWorks Therapeutics, Inc.
Trading Rating : Investor Rating : -
All news about SPRINGWORKS THERAPEUTICS, INC.
News in other languages on SPRINGWORKS THERAPEUTICS, INC.
Analyst Recommendations on SPRINGWORKS THERAPEUTICS, INC.
Chart SPRINGWORKS THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SPRINGWORKS THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
6
Average target price
83,20 $
Last Close Price
79,80 $
Spread / Highest target
9,02%
Spread / Average Target
4,26%
Spread / Lowest Target
-4,76%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
